Literature DB >> 17498893

Comparative quantification of the in vitro activity of veterinary fluoroquinolones.

M Grobbel1, A Lübke-Becker, L H Wieler, R Froyman, S Friederichs, S Filios.   

Abstract

The aim of this study was to compare the in vitro antimicrobial activity of the veterinary fluoroquinolones against a panel of recently isolated porcine and bovine bacterial pathogens. The study used enrofloxacin as a benchmark against which other agents were compared, being the most common fluoroquinolone used in treatment of bovine and porcine infections. The activity of ciprofloxacin was also assessed as it is the main metabolite of enrofloxacin in cattle. Enrofloxacin and ciprofloxacin generally showed higher antibacterial activity, in terms of MIC(50) values, for most pathogen species when compared with marbofloxacin, difloxacin, danofloxacin and norfloxacin. Ciprofloxacin showed significantly greater in vitro antibacterial activity than enrofloxacin against M. haemolytica, P. multocida and E. coli, whereas enrofloxacin showed greater activity than ciprofloxacin against S. aureus. Marbofloxacin was significantly more active than enrofloxacin against M. haemolytica, E. coli and B. bronchiseptica but less active against P. multocida, S. aureus, coagulase negative Staphylococci, S. dysgalactiae, S. uberis, A. pleuropneumoniae and S. suis. Danofloxacin was significantly less active than enrofloxacin against P. multocida, E. coli, S. uberis, A. pleuropneumoniae and S. suis. Enrofloxacin and its metabolite ciprofloxacin showed the highest in vitro activities against most bovine pathogens tested and the porcine pathogens also showed a high degree of sensitivity to enrofloxacin. These data facilitate further pharmacokinetic/pharmacodynamic comparison of fluoroquinolones currently used in veterinary medicine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498893     DOI: 10.1016/j.vetmic.2007.03.017

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.

Authors:  Gareth Lewis; Albert Juhasz; Euan Smith
Journal:  Environ Sci Pollut Res Int       Date:  2012-02-04       Impact factor: 4.223

2.  Cu-Doped Hollow Bioactive Glass Nanoparticles for Bone Infection Treatment.

Authors:  Javier Jiménez-Holguín; Sandra Sánchez-Salcedo; Mónica Cicuéndez; María Vallet-Regí; Antonio J Salinas
Journal:  Pharmaceutics       Date:  2022-04-12       Impact factor: 6.525

3.  Tissue distribution of enrofloxacin in African clawed frogs (Xenopus laevis) after intramuscular and subcutaneous administration.

Authors:  Stephen Felt; Mark G Papich; Antwain Howard; Tyler Long; Gabriel McKeon; Stéphanie Torreilles; Sherril Green
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-03       Impact factor: 1.232

4.  Pharmacokinetic behaviour of enrofloxacin and its metabolite ciprofloxacin after subcutaneous administration in cattle.

Authors:  J J de Lucas; M I San Andrés; F González; R Froyman; C Rodríguez
Journal:  Vet Res Commun       Date:  2008-02-05       Impact factor: 2.459

5.  Occurrence of enrofloxacin in overflows from animal lot and residential sewage lagoons and a receiving-stream.

Authors:  Abua Ikem; Chung-Ho Lin; Bob Broz; Monty Kerley; Ho Le Thi
Journal:  Heliyon       Date:  2017-10-10

6.  Analysis of fluoroquinolones in dusts from intensive livestock farming and the co-occurrence of fluoroquinolone-resistant Escherichia coli.

Authors:  Jochen Schulz; Nicole Kemper; Joerg Hartung; Franziska Janusch; Siegrun A I Mohring; Gerd Hamscher
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

7.  The effect of enrofloxacin on enteric Escherichia coli: Fitting a mathematical model to in vivo data.

Authors:  Samantha Erwin; Derek M Foster; Megan E Jacob; Mark G Papich; Cristina Lanzas
Journal:  PLoS One       Date:  2020-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.